Publications by authors named "Janet Schnee"

Claim this Profile

Mentions over time

Mentions by platform

Video Views

45,530

Total Likes

778

Extended Reach

1,082,342

Social Features

211
C
Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure.
Milton Packer, Stefan D Anker, Javed Butler, Gerasimos Filippatos, Stuart J Pocock, Peter Carson, James Januzzi, Subodh Verma, Hiroyuki Tsutsui, Martina Brueckmann

N Engl J Med· October 2020

Videos about Article: user user user 1

4 2 21 204 8 46 2

View All Article and Social Media Activity
C
Comparison of Investigator-Reported and Centrally Adjudicated Heart Failure Outcomes in the EMPEROR-Reduced Trial.
Peter Carson, John R Teerlink, Michel Komajda, Inder Anand, Stefan D Anker, Janet M Schnee

JACC Heart Fail· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of empagliflozin in heart failure with preserved versus mid-range ejection fraction: a pre-specified analysis of EMPEROR-Preserved.
Stefan D Anker, Javed Butler, Muhammad Shariq Usman, Gerasimos Filippatos, João Pedro Ferreira, Janet M Schnee

Nat Med· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of empagliflozin in patients with heart failure across the spectrum of left ventricular ejection fraction.
Javed Butler, Milton Packer, Gerasimos Filippatos, Joao Pedro Ferreira, Cordula Zeller, Janet Schnee

Eur Heart J· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Regional and ethnic influences on the response to empagliflozin in patients with heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial.
Carolyn S P Lam, João Pedro Ferreira, Egon Pfarr, David Sim, Hiroyuki Tsutsui, Janet Schnee

Eur Heart J· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of Empagliflozin on Worsening Heart Failure Events in Patients With Heart Failure and Preserved Ejection Fraction: EMPEROR-Preserved Trial.
Milton Packer, Javed Butler, Faiez Zannad, Gerasimos Filippatos, Joao Pedro Ferreira, Janet M Schnee

Circulation· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic Importance of NT-proBNP and Effect of Empagliflozin in the EMPEROR-Reduced Trial.
James L Januzzi, Faiez Zannad, Stefan D Anker, Javed Butler, Gerasimos Filippatos, Janet Schnee

J Am Coll Cardiol· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Influence of neprilysin inhibition on the efficacy and safety of empagliflozin in patients with chronic heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial.
Milton Packer, Stefan D Anker, Javed Butler, Gerasimos Filippatos, Joao Pedro Ferreira, Janet Schnee

Eur Heart J· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function: Insights From EMPEROR-Reduced.
Faiez Zannad, João Pedro Ferreira, Stuart J Pocock, Cordula Zeller, Stefan D Anker, Janet Schnee

Circulation· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Baseline characteristics of patients with heart failure with preserved ejection fraction in the EMPEROR-Preserved trial.
Stefan D Anker, Javed Butler, Gerasimos Filippatos, Muhammad Shahzeb Khan, João Pedro Ferreira, Janet M Schnee

Eur J Heart Fail· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of the effects of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR-Preserved Trial.
Stefan D Anker, Javed Butler, Gerasimos S Filippatos, Waheed Jamal, Afshin Salsali, Janet Schnee

Eur J Heart Fail· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of the effect of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR-Reduced trial.
Milton Packer, Javed Butler, Gerasimos S Filippatos, Waheed Jamal, Afshin Salsali, Janet Schnee

Eur J Heart Fail· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A comparison of the safety and effectiveness of dabigatran and warfarin in non-valvular atrial fibrillation patients in a large healthcare system.
Todd C Villines, Janet Schnee, Kathy Fraeman, Kimberly Siu, Matthew W Reynolds

Thromb Haemost· November 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characteristics of patients with non-valvular atrial fibrillation using dabigatran or warfarin in the US.
Nils Schoof, Janet Schnee, Gary Schneider, Melissa Gawlik, Kristina Zint

Curr Med Res Opin· May 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of the acute coronary syndrome safety profile of dabigatran etexilate in patients undergoing major orthopedic surgery: findings from four Phase 3 trials.
Bengt I Eriksson, John J Smith, Joseph Caprini, Stefan Hantel, Andreas Clemens, Janet Schnee

Thromb Res· September 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II*). A randomised, double-blind, non-inferiority trial.
Bengt I Eriksson, Ola E Dahl, Michael H Huo, Andreas A Kurth, Stefan Hantel, Janet M Schnee

Thromb Haemost· April 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dabigatran versus warfarin in the treatment of acute venous thromboembolism.
Sam Schulman, Clive Kearon, Ajay K Kakkar, Patrick Mismetti, Sebastian Schellong, Janet Schnee

N Engl J Med· December 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery.

J Arthroplasty· January 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial.
Bengt I Eriksson, Ola E Dahl, Nadia Rosencher, Andreas A Kurth, C Niek van Dijk, Janet Schnee

Lancet· September 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Osteopontin modulates angiotensin II-induced fibrosis in the intact murine heart.
Alan R Collins, Janet Schnee, Wei Wang, Sarah Kim, Michael C Fishbein

J Am Coll Cardiol· May 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis